← board
DMRA
distress 6/10 · elevated risk$29.67-1%today-13% from 52w high
Lead: mutant-calreticulin-driven myeloproliferative neoplasms
Revenue
pre-revenue
Liquidity
$543M
Runway
21.8 yrs
Shares 1y
+4547%
Price & events
+0.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-1.9%
1W
+29.3%
1M
+16.7%
3M
+15.2%
6M
+681.8%
1Y
+117.4%
2Y
-73.0%
5Y
-90.9%
All
Overview
- Market Cap
- $1.83B
- Volume
- 33.45K
- 52 Week Range
- $2.58 – $34.14
- Total Shares
- 61.55M
- Float Shares
- 41.22M
- Short %
- 6.77%
- % Held by Insiders
- 7.62%
- % Held by Institutions
- 92.49%
- RVOL
- 0.04x
- Beta
- 1.47
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 9
- 2027Guided 40%regulatory submissionFiled (NDA/BLA)DMR-003 · Submit IND or CTA for DMR-003SEC 8-K
- mid-2027Guided 55%readoutDMR-001 · Two POC readouts expected mid-2027SEC 8-K
- beginning mid-2027Guided 55%readoutPhase 1DMR-001 · Present two clinical proof-of-concept datasets for DMR-001SEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)DMR-002 · Submit IND or CTA for DMR-002SEC 8-K
- 2026-08-11earningsEarningsEarnings releaseyahoo
- mid-2026regulatory submissionFiled (NDA/BLA)DMR-001 · Submit IND or CTA for DMR-001SEC 8-K
- 1Q26regulatory submissionFiled (NDA/BLA)GB3226 · IND expected 1Q26SEC 8-K
- 2025-11-10partnershipGalecto merges with Damora TherapeuticsSEC 8-K
- 2024-10-07partnershipBRM-1420 · Acquired global rights to dual ENL-YEATS and FLT3 inhibitor for AML from Bridge Medicines.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $43 (+46% upside) · 8 analysts
- 2026-07-21HC Wainwright & Co.Buy
- 2026-06-12WedbushOutperform
- 2026-06-11HC Wainwright & Co.Buy
- 2026-05-28WedbushOutperform
- 2026-04-24RBC CapitalOutperform
- 2026-03-25Evercore ISI GroupOutperform
Competitors — mutant-calreticulin-driven myeloproliferative neoplasms
- none identified
Recent news
- 2026-07-22Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
- 2026-07-22Damora Therapeutics (DMRA) Proxy filing Summary - Quartr
- 2026-07-21Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
- 2026-07-21DMRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
- 2026-07-20Damora Therapeutics Completes Cayman Islands Redomestication - TipRanks
- 2026-07-17Damora Therapeutics completes redomestication to Cayman Islands - Investing.com
- 2026-07-17Damora Announces Redomestication from Delaware to Cayman Islands - Yahoo Finance UK
- 2026-07-17Damora Announces Redomestication from Delaware to Cayman Islands - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.